Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404-15: Putting IMmotion into Motion: Personalizing Frontline Treatment for Metastatic Renal Cell Carcinoma.
| Autor: | Singla N; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: singlan@mskcc.org. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European urology [Eur Urol] 2020 Jun; Vol. 77 (6), pp. e168-e169. Date of Electronic Publication: 2019 Oct 30. |
| DOI: | 10.1016/j.eururo.2019.09.015 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect